----
Current ValuationThe current P/E ratio is -4.96, within the reasonable range, cheaper than 66.67% of the time in the past 1 years, and the industry ranks 384/608, the industry Median -1.97.
-4.96xP/E
$27.55Stock price
$-5.55Earnings per share
-4.96xP/E
Stock price$27.55Earnings per share$-5.55
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -4.40x
- Typical range
- -5.33x–-3.58x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
013263952
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
GILDUSGilead Sciences | -54.80x | 151.28% | $211.64B |
MRNAUSModerna | -28.09x | 17.02% | $88.52B |
CSLLYUSCSL Limited | -26.29x | -- | $67.79B |
NTRAUSNatera | -310.48x | 5.57% | $59.72B |
RVMDUSRevolution Medicines | -23.19x | 61.94% | $41.00B |
ROIVUSRoivant Sciences | -100.13x | 146.69% | $26.66B |
INSMUSInsmed | -40.60x | 72.84% | $24.59B |
BNTXUSBioNTech SE | -11.33x | 18.75% | $22.15B |
BBIOUSBridgebio Pharma | -24.75x | 28.03% | $14.65B |
SMMTUSSummit Therapeutics | -14.94x | 20.06% | $12.79B |
KYMRUSKymera Therapeutics | -30.13x | 8.57% | $10.53B |
TWSTUSTwist Bioscience | -73.57x | 28.63% | $10.06B |
MDGLUSMadrigal Pharma | -30.59x | 51.30% | $9.94B |
PCVXUSVaxcyte | -9.17x | 47.91% | $9.76B |
IBRXUSImmunityBio | -8.85x | 151.32% | $8.79B |
CYTKUSCytokinetics | -9.80x | 6.85% | $8.76B |
SYREUSSpyre Therapeutics | -56.68x | 45.60% | $8.51B |
ARWRUSArrowHead Pharma | -26.44x | 35,923.70% | $8.46B |
PRAXUSPraxis Precision Medicines | -23.54x | 3.71% | $7.98B |
ABVXUSAbivax SA | -16.23x | 22.99% | $7.55B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
